-
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
Monday, September 20, 2021 - 3:13pm | 452Read More...The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular...
-
Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer
Thursday, August 5, 2021 - 3:12pm | 164Read More...The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid cancer (DTC). The application under priority review covers patients 12 years and older who have progressed following...
-
Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer
Thursday, February 25, 2021 - 12:11pm | 188Read More...The FDA has granted Breakthrough Therapy Designation to Exelixis Inc's (NASDAQ: EXEL) CABOMETYX cabozantinib as a potential treatment for patients with differentiated thyroid cancer progressed following prior therapy and are radioactive iodine-refractory. The company...
